{"id":"NCT02555878","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants","officialTitle":"Efficacy and Safety of Rivaroxaban Prophylaxis Compared With Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-11","primaryCompletion":"2018-08-24","completion":"2018-08-24","firstPosted":"2015-09-22","resultsPosted":"2019-09-12","lastUpdate":"2019-09-12"},"enrollment":841,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Neoplasms"],"interventions":[{"type":"DRUG","name":"Rivaroxaban","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Rivaroxaban","type":"EXPERIMENTAL"},{"label":"Placebo","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to demonstrate that rivaroxaban is superior to placebo for reducing the risk of the primary composite outcome as defined by objectively confirmed symptomatic lower extremity proximal deep vein thrombosis (DVT), asymptomatic lower extremity proximal DVT, symptomatic lower extremity distal DVT, symptomatic upper extremity DVT, symptomatic non-fatal pulmonary embolism (PE), incidental PE, and venous thromboembolism (VTE)-related death in ambulatory adult participants with various cancer types receiving systemic cancer therapy who are at high risk of developing a VTE.","primaryOutcome":{"measure":"Percentage of Participants With Time to First Occurrence of Primary Efficacy Endpoint (Composite and Components)","timeFrame":"Up to Day 180","effectByArm":[{"arm":"Placebo","deltaMin":8.79,"sd":null},{"arm":"Rivaroxaban 10 mg","deltaMin":5.95,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"= 0.101"},{"comp":"OG000 vs OG001","p":"= 0.814"},{"comp":"OG000 vs OG001","p":"= 0.260"},{"comp":"OG000 vs OG001","p":"= 0.538"},{"comp":"OG000 vs OG001","p":"= 0.977"},{"comp":"OG000 vs OG001","p":"= 0.063"},{"comp":"OG000 vs OG001","p":"= 0.301"},{"comp":"OG000 vs OG001","p":"= 0.314"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":151,"countries":["United States","Belgium","Brazil","Bulgaria","Canada","Czechia","France","Germany","Russia","United Kingdom"]},"refs":{"pmids":["34807979","33337539","32663379","30786186","28933799"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":128,"n":404},"commonTop":["Nausea","Anaemia","Fatigue","Diarrhoea","Neutropenia"]}}